Medical Oncology
Overview
Our activity includes 1) treatment of patients with various cancers who require chemotherapy, molecular targeted therapy and immune-checkpoint therapy, 2) clinical and translational researches of oncology, and 3) education/training of medical oncology for undergraduate and graduated students. The department provides Ph. D. course of medical oncology.
Professor:
Yuichi Takiguchi
TEL: +81-43-226-2806
FAX: +81-43-226-2815
e-mail: takiguchi●faculty.chiba-u.jp
URL: http://www.ho.chiba-u.ac.jp/oncol/
※ Please change "●" mark to at-mark if you send emails.
Research & Education
Research topics
- Clinical trials relating drug therapy for lung cancer.
- Clinical trials relating drug therapy for malignant mesothelioma.
- Clinical researches on rare cancers.
- Translational/clinical trials for cancer of unknown primary site.
- Basic researches relating chemo- and/or radio-resistance.
- Basic researches on epithelial-mesenchymal transition.
Education
- Undergraduate education for medical oncology and palliative care.
- Medical oncology training for graduated students and post-graduated trainees.
- Training multi-disciplinary oncology teams.
Recent Publications
- Tanizaki J, Yonemori K, Akiyoshi K, Minami H, Ueda H, Takiguchi Y, et al. Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary. Ann Oncol 2022, 33: 216-226.
- Hayashi H, Takiguchi Y, Minami H, Akiyoshi K, Segawa Y, Ueda H, et al. Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial. JAMA Oncol 2020, 6 : 1931-1938.
- Hida T, Nokihara H, Kondo M, Hak Kim Y, Azuma Y, Seto T, Takiguchi Y, et al. Randomised phase 3 trial of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer. Lancet. 2017, 390: 29-39